Tagged Articles

Zoloft 120 articles

First federal Zoloft birth defects trial scheduled for January 2016

Five cases in an ongoing federal multidistrict litigation (MDL) alleging Pfizer’s antidepressant Zoloft caused heart defects in children born to women who took the drugs during pregnancy have been selected to go to trial, with the first scheduled to begin in January 2016. The first trial is that of plaintiff Deidra Long, who filed her lawsuit in Pennsylvania state court in May 2012. She claims that her son, Hudson Long, was born in January 2008 with congenital birth defects as a result of exposure to Zoloft while in utero. Since his birth, the boy has suffered serious birth defects including ... Read More

Zoloft linked to significant increase in coronary plaque

Laboratory monkeys treated with the antidepressant Zoloft were six times more likely to have a type of coronary plaque called atherosclerosis plaque in their coronary arteries, the primary cause of heart attacks, according to a new study published in the journal Psychosomatic Medicine. It has been widely known for years that depression and heart disease go hand-in-hand. Researchers at Wake Forest Baptist Medical Center wondered if treating depression would reduce heart disease risk. For the study, they fed 42 female monkeys a Western-like diet containing fat and cholesterol for 18 months. During this pre-treatment phase, depressive behavior in the primates was ... Read More

Judge OKs new expert in Zoloft birth defects lawsuit

U.S. District Judge Synthia Rufe ruled that plaintiffs in a multidistrict litigation alleging Zoloft birth defects can introduce a new expert to testify on the association between the antidepressant and cardiac injuries after three others presented by plaintiffs had been excluded by the court for not following proper research methodology. Plaintiffs suing Pfizer will present as a general causation expert witness Nicholas Jewell, a professor at the University of California, Berkeley’s School of Public Health and its statistics department. Judge Rufe ruled that the evidence Jewell is expected to introduce regarding heart risks with Zoloft are of “critical importance” to the plaintiffs’ ... Read More

Mental health groups ask FDA to remove black box warning for suicide risk from antidepressants

Mental health experts are petitioning the Food and Drug Administration (FDA) to remove its severest warning involving suicidal thoughts from the safety labels on all antidepressants because the warning has resulted in a 33 percent increase in suicide attempts, and has scared away some patients who may benefit from the medication. In 2004, the FDA placed a black box warning, its most serious kind, on all categories of antidepressants, indicating that there is an increased suicide risk in children and adolescents treated with the drugs. Two years later, the FDA extended the warning to young adults to age 25 and recommended ... Read More

New meta-analysis raises serious questions about SSRI use during pregnancy

There is not enough research to provide a clear guidance on the risks or benefits of antidepressant use during pregnancy, however there are serious concerns regarding the drugs’ affects on newborns that should be addressed, a new meta-analysis has found. The analysis on antidepressant use during and after pregnancy was conducted by U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality. The study focused on a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, which include the brand names Zoloft, Prozac, Lexapro, Celexa, and Paxil. Researchers reported finding evidence that SSRI use during ... Read More

Celexa, Lexapro birth defects lawsuits returned to state court

Fifteen lawsuits over birth defects in children born to women who took the antidepressants Celexa or Lexapro while pregnant were remanded to state court, a federal judge in Camden, N.J., ruled. Attorneys for the drugs’ maker Forest Laboratories unsuccessfully argued that federal jurisdiction was proper because there were questions about the Food and Drug Administration’s (FDA) labeling of the drugs. Defendants’ claims that Forest Research Institute was fraudulently joined as a defendant were rejected as well. The 15 lawsuits are among 20 that were filed in state courts in New Jersey and removed to federal court by the drug companies. ... Read More

New study suggests SSRI use during pregnancy increases risk of autism spectrum disorders in children

Women using antidepressants known as SSRIs (selective serotonin reuptake inhibitors) during pregnancy may be at higher risk of having children with autism spectrum disorders, according to a new study published in the Journal of Autism and Developmental Disorders. Several studies have raised red flags with the use of SSRIs during pregnancy. SSRIs, which include the brand names Zoloft, Paxil, Lexapro, Celexa and Prozac, have been linked to birth defects such as persistent pulmonary hypertension, heart defects, neural tube defects and malformations. Studies have also suggested that children exposed to SSRIs in utero are more likely to have behavioral problems and ... Read More

Study: Children exposed to SSRIs in utero at greater risk for obesity, type 2 diabetes

Babies born to women who took antidepressants while pregnant are more likely to become obese and develop type 2 diabetes, according to a new study. Obesity and type 2 diabetes in children is already on the rise in the United States and is generally blamed on poor diets and reduced physical activity. However, researchers with McMaster University say that maternal antidepressant use may also be a contributing factor in the pediatric obesity and diabetes epidemic. The study focused on a commonly prescribed type of antidepressant known as selective serotonin reuptake inhibitors, or SSRIs, which include the brand names Prozac, Lexapro, ... Read More

Antidepressant use during pregnancy remains controversial issue

A new study suggesting that there is no increased risk of heart defects in newborns exposed to antidepressants in the first three months of gestation is being criticized by medical experts. “While this is an excellent group of researchers, there are some serious flaws with this study,” says Dr. Adam Urato, maternal-fetal medicine specialist at Tufts Medical Center in Boston. “This isn’t rocket science. We know that exposing developing babies to synthetic chemicals is almost always a really bad idea and should be avoided whenever possible. This study does nothing to alter that common sense concolusion.” The study, conducted by ... Read More

SSRI use in third trimester linked to persistent pulmonary hypertension (PPHN) in newborns

Babies born to women who used SSRI antidepressants during the third trimester of their pregnancies were at an increased risk of giving birth to a baby with persistent pulmonary hypertension in the newborn, or PPHN, according to new research. The study, conducted by researchers with the Sunnybrook Health Sciences Center in Toronto, Canada and the University of Toronto, involved data from seven meta-analyses. Researchers looked at maternal use of SSRIs, or selective serotonin reuptake inhibitors, during different trimesters of pregnancy and the incidence of PPHN. The greatest risk of PPHN was found to be in the third trimester. SSRIs include ... Read More